Determine the necessary mass, volume, or concentration for preparing a solution.
Moligand™,≥98% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC 50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC)
In Vitro
BRD5529 has effective dose-dependent CARD9-TRIM62 inhibitory activity with an IC 50 value of 8.6 μM. BRD5529 directly binds CARD9, but not TRIM62, and disrupt its ubiquitinylation in vitro. BRD5529 (40 μM) produces dose-dependent inhibition of TRIM62-mediated CARD9 ubiquitinylation in vitro. BRD5529 (200 μM, 0-50 min; 200μM, 2-4 h) inhibits CARD9-dependent signaling in innate immune cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HEK293F cells Concentration: 40 μM Incubation Time: Result: Inhibited CARD9 ubiquitinylation reaction in vitro.
In Vivo
BRD5529 (i.p.; 0.1 or 1.0 mg/kg; daily, for 2 weeks) displays no inherent safety concerns in initial general safety and toxicology assessments. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Pneumocystis pneumonia (PCP) modelDosage: 0.1 or 1.0 mg/kg Administration: intraperitoneally (IP), daily, for 2 weeks Result: Resulted no significant changes in daily or final weight gain and proinflammatory cytokines showed no major differences. Showed no significant change of lung, liver, and kidney in pathology scoring.
Form:Solid
IC50& Target:IC50: 8.6 μM (CARD9-TRIM62)
| Canonical Smiles | CC1=CC=C(C=C1)C(=O)NC2=CC(=C(N=C2)N3CCC(CC3)(C(=O)N)N4CCCCC4)C(=O)O |
|---|---|
| IUPAC Name | 2-(4-carbamoyl-4-piperidin-1-ylpiperidin-1-yl)-5-[(4-methylbenzoyl)amino]pyridine-3-carboxylic acid |
| InChIKey | ZXWHESBABUHJBE-UHFFFAOYSA-N |
| INCHI | 1S/C25H31N5O4/c1-17-5-7-18(8-6-17)22(31)28-19-15-20(23(32)33)21(27-16-19)29-13-9-25(10-14-29,24(26)34)30-11-3-2-4-12-30/h5-8,15-16H,2-4,9-14H2,1H3,(H2,26,34)(H,28,31)(H,32,33) |
| Isomeric SMILES | CC1=CC=C(C=C1)C(=O)NC2=CC(=C(N=C2)N3CCC(CC3)(C(=O)N)N4CCCCC4)C(=O)O |
| PubChem CID | 83288403 |
| MeSH Entry Terms | 2-(4-carbamoyl-4-piperidin-1-ylpiperidin-1-yl)-5-((4-methylbenzoyl)amino)pyridine-3-carboxylic acid;BRD5529 |
| Molecular Weight | 465.54 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Amino acids and derivatives - Alpha amino acids and derivatives |
| Direct Parent | Alpha amino acid amides |
| Alternative Parents | p-Toluamides Benzamides Piperidinecarboxamides Pyridinecarboxylic acids Benzoyl derivatives Dialkylarylamines Aminopiperidines Aminopyridines and derivatives Imidolactams Heteroaromatic compounds Vinylogous amides Trialkylamines Amino acids Primary carboxylic acid amides Secondary carboxylic acid amides Carboxylic acids Azacyclic compounds Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Alpha-amino acid amide - P-toluamide - Toluamide - Benzamide - Benzoic acid or derivatives - Piperidinecarboxamide - Pyridine carboxylic acid - Pyridine carboxylic acid or derivatives - Benzoyl - Dialkylarylamine - 4-aminopiperidine - Aminopyridine - Toluene - Monocyclic benzene moiety - Piperidine - Pyridine - Imidolactam - Benzenoid - Heteroaromatic compound - Vinylogous amide - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Amino acid - Carboxamide group - Primary carboxylic acid amide - Carboxylic acid - Azacycle - Organoheterocyclic compound - Organic oxide - Carbonyl group - Organic oxygen compound - Hydrocarbon derivative - Organic nitrogen compound - Organonitrogen compound - Organooxygen compound - Amine - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids. |
| External Descriptors | Not available |
| Solubility | DMSO : 125 mg/mL (268.51 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 465.500 g/mol |
| XLogP3 | -0.100 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 465.238 Da |
| Monoisotopic Mass | 465.238 Da |
| Topological Polar Surface Area | 129.000 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 740.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →